Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs -- Ignore unavailable to you. Want to Upgrade?

To: Druggist who wrote (327)	6/22/1998 12:26:00 PM
From: David Lawrence	Respond to of 384

RESEARCH ALERT-Mylan (NYSE:MYL) estimates raised CHICAGO, June 22 (Reuters) - Gruntal & Co. said Monday it raised earnings estimates and reiterated a strong buy on Mylan Laboratories Inc. -- Raises fiscal 1999 first quarter estimate to $0.27 per share from $0.20, raises third quarter to $0.31 from $0.20 and trims fourth quarter to $0.35 from $0.40. -- Raises full year 1999 estimate to $1.23 a share from $1.20 and 2000 to $1.50 a share from $1.45. -- Says raises estimates after meeting with company management and new numbers could have "much upside surprise stemming from blockbuster new drug candidates and the potential of major acquisitions." -- Sees earnings per share growth of 50 percent this fiscal year, 22 percent next year and 20 percent in fiscal 2001. -- Calls Mylan's prospects "outstanding" and says positive elements include top line revenue growth, expanding profit margins with better mix of sales from high-margined products, numerous selective price increases, and favorable generic drug industry conditions. -- Maintains $40 one-year share price target.